1285513-32-7

Usage

Uses

Used in Medicinal Chemistry:
2-(benzyloxy)-5-bromo-N-(pyridin-3-yl)benzamide is used as a potential drug candidate for its pharmacological properties, which may contribute to the development of new medications for various diseases. Its unique structure, including the benzamide backbone and the presence of a bromo and pyridin-3-yl group, could offer specific therapeutic advantages.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, 2-(benzyloxy)-5-bromo-N-(pyridin-3-yl)benzamide is utilized as a subject of research and development to explore its potential applications in treating different medical conditions. Further studies are necessary to understand its full therapeutic potential and to determine its safety and efficacy in clinical settings.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 62176-31-2 5-bromo-2-[(phenylmethyl)oxy]benzoic acid 
• 89-55-4 5-bromosalicyclic acid 
• 850350-09-3 phenylmethyl 5-bromo-2-[(phenylmethyl)oxy]benzoate 
• 100-39-0 benzyl bromide 

Downstream Products

• 1285515-12-9 2-[(phenylmethyl)oxy]-N-3-pyridinyl-5-(4-pyridinyl)benzamide 
• 1285515-19-6 2-[(phenylmethyl)oxy]-N-3-pyridinyl-5-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]benzamide 
• 1285515-55-0 5-(2-amino-4-pyridinyl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-05-0 5-(1-methyl-1H-pyrazol-5-yl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-06-1 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide 
• 1285515-15-2 2-[(phenylmethyl)oxy]-N,5-di-3-pyridinylbenzamide 
• 1285515-21-0 GSK-2578215A 

Relevant academic research and scientific papers

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors

Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.